Skip to main content

Impact of Targeted Molecular Imaging with 18F-PSMA-1007 and 68Ga-PSMA-11 PET/CT in Multimodal Evaluation of Recurrent Prostate Cancer

Project/agreement No.
lzp-2019/1-0056
Project funding
300 000.00 EUR
Project realization
02.01.2020. - 31.12.2022.

Aim

To specify the imaging biomarkers in recurrent prostate cancer diagnostics, correlating with PSA levels, Gleason score and 68Ga-PSMA-11 and 18F-PSMA-1007 PET/CT ability to visualise prostate cancer local recurrence and distant metastases in reference to other imaging modalities.

Description

Prostate cancer (PCa) is the most common malignant tumor in men in Latvia. More than 1,000 people every year get a PCa diagnosis. In addition, the Baltic States have the highest specific mortality rates for this type of cancer in Europe. In clinically moderate/high risk PCa recurrence occurs up to 30 % after radical treatment, therefore imaging of local and distant metastatic sites is of the utmost importance for selecting appropriate treatment. The plan is to study the utility of PSMA ligand PET/CT in biochemically recurrent PCa with two tracers: 68-Ga-PSMA-11 and 18-F-PSMA-1007: 1) to specify imaging biomarkers in recurrent prostate cancer diagnostics, correlating with PSA levels, Gleason score and PSMA ligand PET/CT ability to visualise prostate cancer local recurrence and distant metastases (oligo-metastatic disease); 2) to evaluate the accuracy of PSMA ligand PET/CT tracers: 68Ga-PSMA-11 and 18-F-PSMA-1007 in reference to other imaging modalities (MRI and bone scintigraphy); 3) to define and compare PSA thresholds for effective diagnostic PSMA ligand PET/CT examinations. The multimodality comparative approach of the 68Ga-PSMA and 18F-PSMA-1007 PET/CT study may advance algorithmic selection of tracers and appropriately affect management decisions for patients with prostate cancer, particularly at the time of biochemical recurrence, to facilitate individual treatment planning, assess outcomes, avoiding unnecessary examinations, therefore improving patients' quality of life.

Project team

  • Maija Radziņa, FLP Project Leader, RSU Lead Researcher, Radiologist
  • Māra Tirāne, RSU Researcher, Radiologist
  • Egils Vjaters, Urologist, Head of Pauls Stradiņš Clinical University Hospital Urology Clinic
  • Lilita Roznere, RSU Researcher, Nuclear Medicine Specialist, Radiation Therapist
  • Laura Saule, FLP Project Student Assistant, Radiology Resident at Pauls Stradiņš Clinical University Hospital

18F-PSMA-1007_un_68Ga-PSMA-11_PET_CT_merketas_molekul_atteldiagn_loma_prostatas_veza_recidiva_multimodala_-izmekl-komanda00.gif

18F-PSMA-1007_un_68Ga-PSMA-11_PET_CT_merketas_molekul_atteldiagn_loma_prostatas_veza_recidiva_multimodala_-izmekl-komanda01.gif

Publications

Maija Radzina, Mara Tirane, Lilita Roznere, Liene Zemniece, Laura Dronka, Marika Kalnina, Edgars Mamis, Juergen Biederer, Vilnis Lietuvietis, Arvis Freimanis, Egils Vjaters, Accuracy of 68 Ga-PSMA-11 PET/CT and multiparametric MRI for the detection of local tumor and lymph node metastases in early biochemical recurrence of prostate cancer, American Journal of Nuclear Medicine and Molecular Imaging, 2020; 10(2): 106–118.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218697/

Theses for conferences in 2020

  • L. Dronka, M. Radzina, M. Tirane, L. Zemniece, M. Kalnina, L. Roznere, I. Briede, V. Lietuvietis, A. Freimanis, E. Vjaters. Impact of Targeted Molecular Imaging with 18F-PSMA-1007 and 68Ga-PSMA-11 PET/CT in Multimodal Evaluation of Local Recurrence of Prostate Cancer. EANM’20 - Annual Congress of the European Association of Nuclear Medicine, October 17-21, 2020, Vienna, Austria
    Control/Tracking Number: 2020-S-1472-EANM
  • M. Tirane; L. Dronka; L. Zemniece; L. Roznere; M. Kalnina; I.Briede; V. Lietuvietis; A. Freimanis; E. Vjaters; M.Radzina. Accuracy of 18F-PSMA-1007 and 68Ga-PSMA-11 PET/CT and Magnetic Resonance Imaging for evaluation a regional lymph nodes in patients with biochemical recurrent prostate cancer. RSNA Annual Meeting. November 29-December 4, 2020, Chicago, USA.
    Abstract ID: 20005096